Long-term incidence of myocardial infarct, stroke, and mortality in patients operated on for abdominal aortic aneurysms

J Vasc Surg. 2012 Feb;55(2):311-7. doi: 10.1016/j.jvs.2011.08.046. Epub 2011 Nov 1.

Abstract

Objective: The risks of myocardial infarction (MI) and stroke after abdominal aortic aneurysm (AAA) resection are not known. Prophylaxis with aspirin and statins is not generally recommended, although patients with AAAs have an increased prevalence of cardiovascular atherosclerosis. We report the incidences of MI, stroke, and death in an unselected national cohort of patients operated on for AAAs, with the general population as the control group.

Methods: In a matched cohort study, 11,094 Danish patients who underwent acute or elective open AAA repair from January 1986 through June 2009 were compared with four randomly chosen age- and sex-matched individuals (controls) from the general population (n = 44,364). Data were collected retrospectively from the Danish Vascular Registry (Karbase), the National Population Registry, and the National Inpatient Registry. The groups were analyzed for the incidences of MI, stroke, and death, with up to 20 years of follow-up.

Results: AAA patients had an annual MI incidence of 2.5% (hazard ratio, 2.1; 95% confidence interval [CI], 1.9-2.2) compared with the general population. The annual incidence of stroke was 2.9% (hazard ratio, 1.8; 95% CI, 1.6-1.9), and there was a 2.4-fold (95% CI, 2.3-2.4) increase in the hazard of all-cause mortality compared with the general population.

Conclusion: AAA patients of both sexes have a high risk of atherosclerotic events (MI, stroke) and death, so lifelong prophylaxis must be considered from our epidemiologic data. Randomized trials investigating the potential benefit of aspirin and statin therapy in AAA patients are needed.

MeSH terms

  • Aged
  • Aortic Aneurysm, Abdominal / mortality*
  • Aortic Aneurysm, Abdominal / surgery*
  • Aspirin / therapeutic use
  • Chi-Square Distribution
  • Denmark / epidemiology
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Incidence
  • Kaplan-Meier Estimate
  • Male
  • Myocardial Infarction / etiology*
  • Myocardial Infarction / mortality*
  • Myocardial Infarction / prevention & control
  • Proportional Hazards Models
  • Registries
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Stroke / etiology*
  • Stroke / mortality*
  • Stroke / prevention & control
  • Time Factors
  • Treatment Outcome
  • Vascular Surgical Procedures / adverse effects*
  • Vascular Surgical Procedures / mortality*

Substances

  • Fibrinolytic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Aspirin